Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

Sandoz, Eli Lilly, Bayer, and Genentech executives tell what strikes them about the 2024 presidential race — and how the ...

Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

A minorities-only study on a dual-action therapy for diabetic macular edema found Hispanic and Latino patients not only ...

The Global Non-Small Cell Lung Carcinoma (NSCLC) Market is on the brink of an extraordinary transformation, with market ...

The company didn't disclose third-quarter numbers. The company said it had completed the acquisition of Genentech's manufacturing facility in Vacaville, Calif., and said its operational and commercial ...